Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET2 | Q6N021 | 4/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | TET3 | O43151 | 1/20 | 0.31 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
| ▸ | ABAT | P80404 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2879158 | 0.83 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL29548444 | 0.81 | GRIK1 (0.44) | TET2ALOX15HSD17B10GRIK1GRIK2 | |
| SCHEMBL6046879 | 0.80 | APEX1 (0.38) | TET2ALOX15HSD17B10GRIK1ALDH1A1 | |
| SCHEMBL8604104 | 0.79 | FFAR3 (0.43) | ALOX15GRIK1GRIK2FFAR3ALDH1A1 | |
| SCHEMBL11842601 | 0.79 | FFAR3 (0.43) | ALOX15GRIK1GRIK2FFAR3ALDH1A1 | |
| SCHEMBL9453790 | 0.79 | AKR1B1 (0.42) | ALOX15HSD17B10ALDH1A1TSHR | |
| Methacrylic Acid SCHEMBL6560561 | 0.79 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL9117550 | 0.77 | FNTA (0.44) | ALOX15HSD17B10ALDH1A1TSHR | |
| SCHEMBL11190671 | 0.77 | FNTA (0.44) | ALOX15HSD17B10ALDH1A1TSHR | |
| SCHEMBL9343451 | 0.77 | FNTA (0.44) | ALOX15HSD17B10ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 354 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173284-A1 | EFLORNITHINE AND SULINDAC, FIXED DOSE COMBINATION FORMULATION | CANCER PREVENTION PHARMACEUTICALS, INC. (US) | 2024-05-30 | — | — | US | claimed |
| US-20240091201-A1 | FORMULATIONS OF DEFERASIROX AND METHODS OF MAKING THE SAME | AustinPx, LLC (US) | 2024-03-21 | — | — | US | claimed |
| US-11878005-B2 | Formulations of deferasirox and methods of making the same | AustinPx, LLC (US) | 2024-01-23 | — | — | US | claimed |
| US-20230218533-A1 | 3D LASER SINTERING PROCESSES FOR IMPROVED DRUG DELIVERY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-07-13 | — | — | US | claimed |
| US-20230167181-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MANUFACTURE USING THERMALLY CONDUCTIVE EXCIPIENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-06-01 | — | — | US | claimed |
| WO-2023086832-A1 | METHODS OF PREPARING DOSAGE FORMS USING 3D PRINTING CONTAINING AMORPHOUS SOLID DISPERSIONS | BOARD OF REGENTS, THE UNIVERSITY OFTEXAS SYSTEM (US) | 2023-05-19 | — | — | WO | claimed |
| EP-4164618-A1 | 3D LASER SINTERING PROCESSES FOR IMPROVED DRUG DELIVERY | Board of Regents, The University of Texas System (US) | 2023-04-19 | — | — | EP | claimed |
| US-20220402884-A1 | (S)-N-HYDROXY-2-(2-(4-METHOXYPHENYL)BUTANAMIDO)THIAZOLE-5-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2022-12-22 | — | — | US | claimed |
| US-11420947-B2 | (S)-n-hydroxy-2-(2-(4-methoxyphenyl)butanamido)thiazole-5-carboxamide and pharmaceutically acceptable salts thereof | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2022-08-23 | — | — | US | claimed |
| WO-2021252793-A1 | 3D LASER SINTERING PROCESSES FOR IMPROVED DRUG DELIVERY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-12-16 | — | — | WO | claimed |
| US-20140039031-A1 | PHARMACEUTICAL FORMULATIONS OF ACETYL-11-KETO-B-BOSWELLIC ACID, DIINDOLYLMETHANE, AND CURCUMIN FOR PHARMACEUTICAL APPLICATIONS | Dispersol Technologies. LLC (US) | 2014-02-06 | — | — | US | claimed |
| WO-2012116238-A1 | PHARMACEUTICAL FORMULATIONS OF ACETYL-11-KETO-β-BOSWELLIC ACID, DIINDOLYLMETHANE, AND CURCUMIN FOR PHARMACEUTICAL APPLICATIONS | DISPERSOL TECHNOLOGIES, LLC (US) | 2012-08-30 | — | — | WO | claimed |
| EP-2486918-A2 | PHARMACEUTICAL COMPOSITION WITH BOTH IMMEDIATE AND EXTENDED RELEASE CHARACTERISTICS | Yungjin Pharm. Co. Ltd. (KR) | 2012-08-15 | — | — | EP | claimed |
| US-20110217374-A1 | PHARMACEUTICAL COMPOSITION SIMULTANEOUSLY HAVING RAPID-ACTING PROPERTY AND LONG-ACTING PROPERTY | YUNGJIN PHARM. CO., LTD. (KR) | 2011-09-08 | — | — | US | claimed |
| US-6752953-B2 | HEATING A CAPSULE FORMING COMPOSITION IN A MOLD, FOLLOWED BY INSERTING A PESTLE INTO THE MOLD TO COAT THE MELTED CAPSULE FORMING COMPOSITION ONTO THE PESTLE. | YUNG SHIN PHARMACEUTICAL CO., LTD. (TW) | 2004-06-22 | — | — | US | claimed |
| US-20030161872-A1 | Capsule for holding liquid-containing compositions and method for making the same | YUNG SHIN PHARMACEUTICAL INDUSTRIAL CO., LTD. (TW) | 2003-08-28 | — | — | US | claimed |
| EP-1235556-A4 | TASTE MASKING COATING COMPOSITIONS | RANBAXY LAB LTD (IN) | 2003-07-16 | — | — | EP | claimed |
| US-20030104047-A1 | Method for manufacturing hard non-gelatin pharmaceutical capsules | YUNG SHIN PHARMACEUTICAL INDUSTRIAL CO., LTD. (TW) | 2003-06-05 | — | — | US | claimed |
| EP-1235556-A2 | TASTE MASKING COATING COMPOSITIONS | RANBAXY LABORATORIES, LTD. (IN) | 2002-09-04 | — | — | EP | claimed |
| WO-2000056266-A2 | TASTE MASKING COATING COMPOSITIONS | RANBAXY LABORATORIES LIMITED (US) | 2000-09-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240091201-A1 | FORMULATIONS OF DEFERASIROX AND METHODS OF MAKING THE SAME | FECH, PFKP, DUT | TET2 199/4885ALOX15 188/4885HSD17B10 1493/4885 |
| US-20030161872-A1 | Capsule for holding liquid-containing compositions and method for making the same | C5, RCC1, DEPTOR | TET2 1605/4885ALOX15 134/4885HSD17B10 1390/4885 |
| US-20220402884-A1 | (S)-N-HYDROXY-2-(2-(4-METHOXYPHENYL)BUTANAMIDO)THIAZOLE-5-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | HDAC5, HDAC2, HDAC3 | TET2 1348/4885ALOX15 4057/4885HSD17B10 163/4885 |
| US-11878005-B2 | Formulations of deferasirox and methods of making the same | FECH, PFKP, DUT | TET2 199/4885ALOX15 188/4885HSD17B10 1493/4885 |
| US-11420947-B2 | (S)-n-hydroxy-2-(2-(4-methoxyphenyl)butanamido)thiazole-5-carboxamide and pharmaceutically acceptable salts thereof | HDAC5, HDAC2, HDAC3 | TET2 1348/4885ALOX15 4057/4885HSD17B10 163/4885 |
| US-20030104047-A1 | Method for manufacturing hard non-gelatin pharmaceutical capsules | PGA5, DSTN, RPS5 | TET2 1281/4885ALOX15 1169/4885HSD17B10 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.